Key result
Active cancer links to fewer clinical events preceding anticoagulant nonpersistence than non-cancer patients.
Why the study?
Nonpersistence in anticoagulation therapy is common and linked to undesirable clinical outcomes in patients with VTE, but preceding clinical events across cancer status remain to be clarified.
What clinical events precede anticoagulant treatment nonpersistence in patients with venous thromboembolism, and does this differ by active cancer status?
Cohort (n=55,759)
What clinical events precede anticoagulant treatment nonpersistence in patients with venous thromboembolism, and does this differ by active cancer status?
Clinically significant events frequently trigger anticoagulant nonpersistence in VTE, but the distribution of these events differs significantly in the presence of active cancer.
Answers are grounded in this paper and cite their sources.
Events often precede nonpersistence in VTE anticoagulation; hypothesis-generating for cancer-specific persistence strategies.
BACKGROUND: Nonpersistence in anticoagulation therapy is common and associated with undesirable clinical outcomes in patients with venous thromboembolism (VTE). METHODS: We investigated preceding clinical events of treatment nonpersistence (e.g., switching, discontinuing, or restarting) in VTE patients with and without active cancer using Korean claims database. RESULTS: Clinically significant events including thromboembolic events, hepatic function change and surgery preceded treatment nonpersistence, but heterogeneous distributions of clinical events were observed in the presence of active cancer. Patients with active cancer had a low rate of clinical events preceding treatment nonpersistence, and new active cancer diagnosis in the nonactive cancer group was most common before the switch to parenteral anticoagulants from warfarin or non-vitamin K antagonist oral anticoagulants (NOACs). CONCLUSION: These findings suggest that clinically significant events can precede treatment nonpersistence and largely paralleled current guidelines for patients with VTE, whereas heterogeneous distributions of clinical events were observed in the presence of active cancer.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2023) conducted a cohort in Venous Thromboembolism (VTE) (n=55,759). Active cancer vs. No active cancer was evaluated on Anticoagulant treatment nonpersistence (switch, discontinuation, or interruption). Clinically significant events, such as thromboembolic events and major surgery, frequently preceded anticoagulant nonpersistence, though patients with active cancer had a lower rate of these preceding events.
Synapse has enriched 10 related papers. Consider them for comparative context: